<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227328</url>
  </required_header>
  <id_info>
    <org_study_id>IRST174.19</org_study_id>
    <secondary_id>2016-004107-31</secondary_id>
    <nct_id>NCT03227328</nct_id>
  </id_info>
  <brief_title>CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO</brief_title>
  <acronym>KENDO</acronym>
  <official_title>Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agenzia Italiana del Farmaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label, multicenter, group sequential response adaptive randomized phase 2&#xD;
      study, comparing two treatments for locally advanced or metastatic luminal breast cancer:&#xD;
&#xD;
        -  Arm A: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor (palbociclib,&#xD;
           ribociclib or abemaciclib) plus endocrine therapy (aromatase inhibitor [AI] or&#xD;
           fulvestrant)&#xD;
&#xD;
        -  Arm B: chemotherapy plus endocrine therapy (AI or fulvestrant, administered either&#xD;
           concomitantly from the beginning of chemotherapy or sequentially after 4-6 months of&#xD;
           chemotherapy) Treatments will continue until disease progression or toxicity or patient&#xD;
           refusal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group sequential response adaptive randomized clinical trial of concomitant chemotherapy plus&#xD;
      endocrine therapy versus cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine&#xD;
      therapy for advanced hormone receptor-positive, HER2-negative breast cancer Primary&#xD;
      Objective: To compare the efficacy of concomitant CDK4/6 inhibitor plus endocrine therapy&#xD;
      versus chemotherapy plus endocrine therapy (administered either concomitantly from the&#xD;
      beginning or sequentially) in terms of progression-free survival (PFS).&#xD;
&#xD;
      Secondary objectives: To compare between treatment arms:&#xD;
&#xD;
        -  quality of life (EORTC quality of life questionnaire(QLQ) QLQ -C30 and QLQ-BR23)&#xD;
&#xD;
        -  toxicity (CTCAE version 5.0)&#xD;
&#xD;
        -  time to treatment failure&#xD;
&#xD;
        -  best response rate&#xD;
&#xD;
        -  duration of response&#xD;
&#xD;
        -  clinical benefit rate&#xD;
&#xD;
        -  overall survival (OS)&#xD;
&#xD;
        -  PFS and clinical benefit with the subsequent line of treatment after cross-over: CDK4/6&#xD;
           inhibitors plus endocrine therapy in patients treated with chemotherapy plus endocrine&#xD;
           therapy, chemotherapy (with or without endocrine therapy) in patients treated with&#xD;
           CDK4/6 inhibitors plus endocrine therapy&#xD;
&#xD;
        -  correlative biomarkers of response to CDK4/6 inhibitors and chemotherapy:&#xD;
&#xD;
             -  tissue markers (on the primary tumor and / or metastatic tissue)&#xD;
&#xD;
             -  circulating markers (e.g. CTCs, ctDNA)&#xD;
&#xD;
      The patients will be allocated according to block randomization until two events are observed&#xD;
      in each arm, and then according to the time-to-event adaptation of the group sequential&#xD;
      Doubly-adaptive Biased Coin Design (DBCD) whose allocation probabilities are computed at the&#xD;
      end of the block randomization and after around 70% and 85% of the 150 maximum patients are&#xD;
      enrolled during a 23 month period. At these last two (i.e. after 105 and 128 patients,&#xD;
      respectively), interim analysis on efficacy will be carried out allowing for early stopping.&#xD;
      At the end of the 16-month follow up, administrative censoring is introduced. Therefore, the&#xD;
      total study duration is 39 months.&#xD;
&#xD;
      Previous results on palbociclib and fulvestrant combination in second line and the&#xD;
      characteristics of our target population lead us to assume a median PFS of 8 and 12 months&#xD;
      for arm A and B, respectively. Under this scenario, for a sample size of at the most 150&#xD;
      patients, the proposed design strategy has led to a simulated power of 0.911 compared with a&#xD;
      0.717 one for the Complete Randomisation design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>group sequential response adaptive Randomized, open label, multicenter,</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 39 months</time_frame>
    <description>time from randomization until first disease progression or death; disease progression is defined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 quality of life between the 2 arms</measure>
    <time_frame>up to 39 months</time_frame>
    <description>evaluation of EORTC QLQ-C30 Version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-BR23 quality of life between the 2 arms</measure>
    <time_frame>up to 39 months</time_frame>
    <description>evaluation of QLQ-BR23 (breast cancer specific)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>up to 39 months</time_frame>
    <description>evaluation of toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure (TTF)</measure>
    <time_frame>up to 39 months</time_frame>
    <description>the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient refuse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best objective response rate</measure>
    <time_frame>up to 39 months</time_frame>
    <description>best objective (partial or complete) response rate according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>up to 39 months</time_frame>
    <description>time from documentation of tumor response to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate (CBR)</measure>
    <time_frame>up to 39months</time_frame>
    <description>the percentage of patients who achieved complete response, partial response or stable disease lasting longer than 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 39 months</time_frame>
    <description>time from randomization until death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 39 months</time_frame>
    <description>PFS and clinical benefit with the subsequent line of treatment after cross-overtime calculated from randomization until the date of start of the subsequent treatment line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlative biomarkers of response to chemotherapy and endocrine therapy</measure>
    <time_frame>up to 39 months</time_frame>
    <description>correlative biomarkers assessed on baseline tumor specimens (from primary tumor or metastatic biopsies) and blood samples collected at baseline and at different timepoints until evidence of disease progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hormone Receptor Positive Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Hormone Receptor Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy</intervention_name>
    <description>CDK4/6 inhibitor:&#xD;
palbociclib&#xD;
ribociclib&#xD;
abemaciclib&#xD;
Endocrine therapy:&#xD;
non-steroidal or steroidal AI&#xD;
fulvestrant</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)</intervention_name>
    <description>Standard Chemotherapy regimens will be classified as:&#xD;
anthracycline + taxane,&#xD;
taxane,&#xD;
anthracycline,&#xD;
capecitabine / fluoropyrimidines,&#xD;
others.&#xD;
Endocrine therapy:&#xD;
non-steroidal or steroidal AI&#xD;
fulvestrant</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of HR-positive (ER ≥10% of tumor cells), HER2-negative breast&#xD;
             cancer, determined by local laboratory on most recent available tumor tissue.&#xD;
&#xD;
          -  Locally advanced (not susceptible to locoregional therapy) or metastatic disease&#xD;
             (herein globally defined as &quot;advanced breast cancer (ABC)&quot;).&#xD;
&#xD;
          -  At least one of the following signs of disease aggressiveness:&#xD;
&#xD;
               -  The main criteria are a low expression of ER (10% ≤ ER &lt; 50%) and/or a relapse&#xD;
                  while on the first 2 years of adjuvant endocrine therapy or disease progression&#xD;
                  (PD) within the first 6 months of first-line endocrine therapy for ABC&#xD;
&#xD;
               -  Other tumor characteristics of aggressiveness that make the patient potentially&#xD;
                  candidate to chemotherapy, according to the guidelines of the Italian Association&#xD;
                  of Medical Oncology [AIOM guidelines 2017], such as: elevated Ki67 (preferably&#xD;
                  documented, if available, on a metastatic biopsy), low expression of hormone&#xD;
                  receptors (e.g. progesterone receptor &lt;20%), extended visceral involvement or&#xD;
                  visceral involvement at risk for organ failure, uncontrolled symptoms; these&#xD;
                  patients are eligible if chemotherapy is considered a suitable option by the&#xD;
                  treating physician.&#xD;
&#xD;
          -  Postmenopausal women, or premenopausal women undergoing treatment with LHRH analog, or&#xD;
             men (either receiving treatment with LHRH analog or not).&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 criteria, or not measurable but evaluable&#xD;
             disease.&#xD;
&#xD;
          -  Any prior adjuvant chemotherapy or endocrine therapy&#xD;
&#xD;
          -  No prior chemotherapy for advanced disease.&#xD;
&#xD;
          -  Up to one prior line of endocrine therapy for ABC.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤2 (see Appendix A).&#xD;
&#xD;
          -  Adequate organ (renal, hepatic, bone marrow, cardiac) functions.&#xD;
&#xD;
          -  Female participants of child bearing potential and male participants whose partner is&#xD;
             of child bearing potential must be willing to use effective contraception during the&#xD;
             study period and for 4 months thereafter. Effective contraception methods include:&#xD;
             total abstinence (when this is in line with the preferred and usual lifestyle of the&#xD;
             subject); tubal ligation; male sterilization; combination of the placement of an&#xD;
             intrauterine device or intrauterine system and barrier methods of contraception with&#xD;
             spermicidal suppository.&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior chemotherapy or CDK4/6 inhibitor for advanced breast cancer&#xD;
&#xD;
          -  More than 1 prior line of endocrine therapy for ABC.&#xD;
&#xD;
          -  Patients who have not recovered from adverse events due to prior therapies to grade ≤1&#xD;
             (excluding alopecia).&#xD;
&#xD;
          -  Active central nervous system metastases.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to the drugs used in the study.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Prior history of non-breast malignancy (except for adequately controlled basal cell&#xD;
             carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the&#xD;
             bladder), unless treated with curative intent and disease free for at least 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Rocca</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 40, 47014 Meldola, ITALY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana Nanni</last_name>
    <phone>+390543739266</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O. Oncologia Medica, P.O. Bellaria-Maggiore</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alba Brandes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alba Brandes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica IRST IRCCS</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rocca</last_name>
      <phone>0543739100</phone>
      <email>andrea.rocca@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Rocca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Interna e Riabilitazione - U.O. Medicina Interna Oncologica, Ospedale Ramazzini</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Artioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Artioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. Oncologia-Ematologia - U.O. Oncologia Medica,Azienda USL di Piacenza - Ospedale Civile</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica AUSL Romagna-Ravenna</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Amaducci, MD</last_name>
      <email>laura.amaducci@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Laura Amaducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica AUSL Romagna-Rimini</name>
      <address>
        <city>Rimini</city>
        <state>RI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni, MD</last_name>
      <email>lorenzo.gianni@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Gianni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti Umberto I - GM Lancisi - G Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rossana Berardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rossana Berardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica; Ist. Tumori Giovanni Paolo II - IRCCS Osp. Oncologico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vito Lorusso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vito Lorusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terapia Molecolare e Farmaco Genomica, Azienda Socio-Sanitaria Territoriale di Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Generali, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Generali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Ferrara Arcispedale Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Frassoldati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Guastalla - AUSL di Reggio Emilia</name>
      <address>
        <city>Guastalla</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Giovanardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Giovanardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL Imola</name>
      <address>
        <city>Imola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Maestri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Maestri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis - Azienda ULSS9 Scaligera</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Bonetti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Macerata, ASUR AV3</name>
      <address>
        <city>Macerata</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Battelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Battelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Piacentini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Federico Piacentini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità di Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Gennari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Gennari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica, AOU di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Musolino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Musolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria della Misericordia di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Roila, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fausto Roila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Arcispedale S. Maria Nuova IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giancarlo Bisagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio - ASST Valtellina e Alto Lario</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Bertolini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Bertolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive Breast Cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>First line treatment</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>randomized phase III trial</keyword>
  <keyword>aromatase inhibitor</keyword>
  <keyword>HR-negative Breast Cancer</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

